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Abstract
Introduction Phosphoinositide 3-kinase (PI3K)-activated
signalling has a critical role in the evolution of aggressive
tumourigenesis and is therefore a prime target for anticancer
therapy. Previously we have shown that the  galactoside
binding protein (GBP) cytokine, an antiproliferative molecule,
induces functional inhibition of class 1A and class 1B PI3K.
Here, we have investigated whether, by targeting PI3K, GBP
has therapeutic efficacy in aggressive breast cancer cells where
strong mitogenic input is fuelled by overexpression of the ErbB2
(also known as HER/neu, for human epidermal growth factor
receptor 2) oncoprotein receptor and have used immortalised
ductal cells and non-aggressive mammary cancer cells, which
express ErbB2 at low levels, as controls.
Methods Aggressive BT474 and SKBR3 cancer cells where
ErbB2 is overexpressed, MCF10A immortalised ductal cells and
non-invasive MCF-7 cancer cells which express low levels of
ErbB2, both in their naive state and when forced to mimic
aggressive behaviour, were used. Class IA PI3K was
immunoprecipitated and the conversion of phosphatidylinositol
(4,5)-biphosphate (PIP2) to phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) assessed by ELISA. The consequences of
PI3K inhibition by GBP were analysed at proliferation level, by
extracellular signal-regulated kinase (ERK) activation, by akt
gene expression and by apoptosis. Apoptosis was documented
by changes in mitochondrial membrane potential, alteration of
the plasma membrane, caspase 3 activation and DNA
fragmentation. Phosphorylated and total ERK were measured by
Western blot analysis and akt mRNA levels by Northern blot
analysis. The results obtained with the BT474 and SKBR3 cells
were validated in the MCF10A ductal cells and in non-invasive
MCF-7 breast cancer cells forced into mimicking the in vitro
behaviour of the BT474 and SKBR3 cells.
Results In aggressive breast cancer cells, where mitogenic
signalling is enforced by the ErbB2 oncoprotein receptor,
functional inhibition of the catalytic activity of PI3K by the GBP
cytokine and loss of akt mRNA results in apoptotic death. A
functional correlation between ERK and the kt gene was also
found. The relationship between ERK, akt mRNA, PI3K and cell
vulnerability to GBP challenge was sustained both in mammary
ductal cells forced to mimic an aggressive behaviour and in non-
aggressive breast cancer cells undergoing an enforced shift into
an aggressive phenotype.
Conclusions GBP, a newly discovered physiological inhibitor
of PI3K, is a selective and potent inducer of apoptosis in
aggressive breast cancer cells. Due to its physiological nature,
which carries no chemotherapeutic disadvantages, GBP has
the potential to be safely tested in clinical trials.
GBP:  galactoside binding protein; DMEM: Dulbecco's modified Eagle Medium; EGF: epidermal growth factor; ELISA: enzyme-linked immunosorb-
ent assay; ERK: extracellular signal-related kinase; PBS: phosphate-buffered saline; PI3K: phosphoinositide 3-kinase; PIP2: phosphatidylinositol 
(4,5)-biphosphate; PIP3: phosphatidylinositol (3,4,5)-trisphosphate; TUNEL: terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end 
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Introduction
The biological behaviour of cancer cells and their response to
therapies is determined by their mutational repertoire, of which
change leading to enhanced mitogenic signalling is one
aspect. Genetic alterations, which in cancer cells magnify
mitogenic signalling and are a cause of aggressive disease
and resistance to therapies, include amplification of the ErbB2
(also known as HER/neu, for human epidermal growth factor
receptor 2) gene, present in many types of cancer and fre-
quent in breast, ovarian and stomach carcinomas [1].
ErbB2 is a ligand-less member of the ErbB/epidermal growth
factor (EGF) tyrosine kinase receptor family that enhances
mitogenic signalling: by being constitutively active, by dimeris-
ing as a preferred partner with other ErbB members that in
breast cancer can also be overexpressed, and by resisting
endocytic degradation and returning to the cell surface [2-5].
Phosphorylated tyrosine residues in the cytoplasmic tail of the
ErbB2 molecule lead to the formation of high affinity binding
sites for the Src homology 2 (SH2) domains of Src homology
2 containing (Shc) and growth factor receptor-bound protein
2 (Grb2) adapter proteins [6,7], the binding of the nucleotide
exchange factor son of Sevenless (SOS) to the SH3 domains
of Grb2 and the conversion of GDP-Ras to active GTP-Ras
which mediates the activation of effector pathways that trans-
duce proliferative signalling [8,9]. Critically, by interacting with
the catalytic subunits of class IA [10] and class IB [11-13]
phosphoinositide 3-kinase (PI3K), activated Ras can contrib-
ute to coupling mitogenic input with survival ability.
Class I PI3Ks are a central feature of many signalling pathways
that allow cells to withstand apoptotic stimuli and secure
mitogenic expansion. By catalysing the conversion of phos-
phatidylinositol (4,5)-biphosphate (PIP2) to phosphatidylinosi-
tol (3,4,5)-trisphosphate (PIP3), PI3K enables Akt/protein
Kinase B (PKB) recruitment to the plasma membrane where
Akt is activated to become the principal effector of survival sig-
nalling [14,15]. Phosphorylation of downstream targets such
as Bad, forkhead transcription factors, IB kinase (IKK), cas-
pase 9 and Yes-associated proteins (YAPs) by activated Akt
confers resistance to apoptosis [16-19]. Furthermore, acti-
vated Akt has also a role in promoting cell growth and cell pro-
liferation via phosphorylation and repression of the forkhead
box O (FOXO) family of transcription factors and phosphoryla-
tion and inhibition of glycogen synthetase kinase-3 [20].
Class IA PI3K is specifically implicated in the pathogenesis of
cancer. High frequency of somatic mutations in the PI3K cat-
alytic subunit (PI3KCA) gene [21,22], results in constitutively
active mutants which have the capacity to transform normal
cells into cancer cells and to be oncogenic in vivo [23-25].
The importance of PI3K in cancerogenesis is further indicated
by the evidence that many aggressive and drug resistant
tumour cells display elevated levels of PIP3 as a result of phos-
phatase and tensin homolog (PTEN) deletion [26].
The role of the PI3K signalling network in cell proliferation, cell
survival and, through PI3K interaction with Rac proteins, in cell
motility and migration [15,27], all processes of central impor-
tance to the evolution of aggressive tumourigenesis, has pro-
vided scope for the design of anticancer drugs aimed at PI3K
and its downstream effectors [28,29,18]. However, there is
now evidence that inhibition of PI3K activity can be achieved
without chemotherapeutic disadvantages following physiolog-
ical routes. We have recently shown that monomeric -galac-
toside binding protein (GBP), a molecule that we first
discovered to be an endogenous negative cell cycle regulator
[30] and that we then identified as a cytokine [31], is a natural
physiological inhibitor of class IA and class IB PI3K [32].
Through functional inhibition of p110,  GBP induces
downregulation of PI3K activity, suppression of Ras-GTP load-
ing, consequent loss of extracellular signal-regulated kinase
(ERK) activation and block of cell proliferation [32].
In this study we have used the recombinant form of the human
GBP cytokine to investigate its effect in aggressive cancer
cells where the ErbB2 oncoprotein receptor is overexpressed,
taking as a paradigm cancer of the breast, known for high
mutation frequency in the gene encoding the p110 subunit
of PI3K [22,25]. In addition we have used immortalised mam-
mary ductal cells and non-invasive breast cancer cells, where
ErbB2 is at low levels, both in their naïve state and when
forced to mimic aggressiveness as represented by the in vitro
behaviour of the cells which overexpress ErbB2.
We provide the first evidence that PI3K activity is a require-
ment for akt gene expression and that inhibition of PI3K activity
by the GBP cytokine and loss of Akt gene expression is fol-
lowed by apoptotic death in ErbB2 aggressive cancer cells
and in cells forced to mimic their in vitro behaviour, but not in
naïve mammary ductal cells.
Materials and methods
Cell lines
The BT474 cells (Cancer Research UK, London, UK) were
cultured in DMEM/F12 with 10% foetal calf serum (FCS) (Inv-
itrogen, Renfrew, UK) and 20 g/ml insulin (Sigma, Dorset,
UK); the SKBR3 cells (Cancer Research UK) were grown in
DMEM (Invitrogen) plus 10% FCS. MCF10A, MCF10AV12Ras
(Cancer Research UK) and MCF10ACTx cells were grown in
DMEM/F12 plus 5% horse serum (Invitrogen), 10 g/ml insu-
lin, 5 g/ml hydrocortisone (Calbiochem, San Diego, CA,
USA) and 20 g/ml epidermal growth factor (Calbiochem),
plus 100 ng/ml cholera toxin (Sigma) in the case of the
MCF10ACTx  cells. Cultures were incubated at 37°C in a
humidified atmosphere of 5% CO2 in air.
Apoptosis assays
Tetramethylrhodamine ethyl ester (TMRE) (Molecular Probes/
Invitrogen) staining was used to assess loss of mitochondrial
membrane potential. Redistribution of plasma membraneAvailable online http://breast-cancer-research.com/content/11/1/R2
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phosphatidylserine was assessed using annexin V-fluorescein
isothiocyanate (FITC) (Pharmingen, San Diego, CA, USA).
Caspase 3 activity was measured by cleavage of non-fluores-
cent PhiPhiLux to a fluorescent product (Oncoimmunin, Gaith-
ersburg, MD, USA). Strand break DNA fragmentation was
analysed by terminal deoxynucleotidyl transferase (TdT)-medi-
ated dUTP nick-end labelling (TUNEL) using the Apo-Brdu kit
(Phoenix Flow Systems, Phoenix, AZ, USA)) and analysed by
fluorescence-activated cell sorting (FACS) using a FACS Cal-
ibur (Becton Dickinson, San Jose, CA, USA) system. All meth-
ods were carried out according to the manufacturers'
instructions.
PI3K assays
For direct functional assessment of PI3K activity, class IA PI3K
was isolated by immunoprecipitation using an antibody to the
p85 adapter subunit and the ability of the coprecipitated cata-
lytic p110 catalytic subunit to convert a standard PIP2 to PIP3
in a kinase reaction assessed by measuring the generated
PIP3 by competitive ELISA.
5 × 106 cells were washed three times with 137 mM NaCl, 20
mM Tris HCl pH7.4, 1 mM CaCl2, 1 mM MgCl2, 0.1 mM Na
orthovanadate (Sigma) (buffer A) and lysed in 1 ml of the same
buffer supplemented with 1 mM phenylmethylsulphonyl fluo-
ride (PMSF) (Sigma) and 1% nonyl phenoxylpolyethoxyletha-
nol (NP40) (Calbiochem) for 20 min on ice. Lysates were
centrifuged at 13,000 rpm for 10 min to remove insoluble
material and the supernatants stored at -80°C. Frozen lysates
containing 600 g protein were thawed on ice and PI3K was
immunoprecipitated by incubation with 5 l anti-PI3K p85
(Upstate Biotechnology, Lake Placid, NY, USA) for 1 h at 4°C
on a rotating wheel, followed by addition of 60 l of a 50%
slurry of Protein A agarose (Sigma) beads in PBS for 1 h at
4°C. The immunoprecipitated enzyme was collected by cen-
trifugation at 13,000 rpm for 10 s. Pellets were washed three
times in buffer A plus 1% NP40, three times in 0.1 M Tris-HCl,
pH 7.4, 5 mM LiCl, 0.1 mM Na orthovanadate and twice with
10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM ethylenediami-
netetraacetic acid (EDTA), 0.1 mM Na orthovanadate. Pellets
resuspended in 110 l kinase reaction buffer (5 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH
7.0, 2.5 mM MgCl2, 25 M ATP) were incubated in a water
bath for 3 h at 37°C with 40 pmol PI(4,5)P2 substrate (Eche-
lon Biosciences, Salt Lake City, UT, USA). The reaction was
stopped with EDTA at a final concentration of 5 mM and the
reaction mixture centrifuged at 13,000 rpm at 4°C. Superna-
tants were transferred to a microtitre plate for a competitive
ELISA (Echelon Biosciences K-1000) to quantify the PIP3
generated in the kinase reaction. Duplicate 50 l volumes of
the supernatants were each incubated with 50 l of anti-PIP3
antibody for 1 h at room temperature. The reaction mixture was
then transferred to a microtitre plate coated with PIP3 and
incubated for 1 h in the dark. After three washes with Tris-buff-
ered saline (TBS) plus 0.05% Tween 20 (Sigma), 100 l of
horseradish peroxidase (HRP)-conjugated antibody to the
anti-PIP3 was added to each well and incubated for 1 h at
room temperature in the dark. Following three further washes
with TBS plus 0.05% Tween 20, 100 l of tetramethyl benzi-
dine (TMB) substrate (Echelon Biosciences) was added and
the reaction was stopped after an appropriate time (approxi-
mately 20 min) with 100 l 0.5 M H2SO4. Absorbance of the
samples was measured at 450 nm and the PIP3 was quanti-
fied by comparison with a PIP3 standard curve carried out in
parallel with the experimental samples and plotted on a log
scale.
Northern blot analysis
Total RNA was extracted from cells using Trizol reagent (Invit-
rogen) according to the manufacturer's instructions. A total of
10 g RNA was run on 2.2 M formaldehyde/1.25% agarose
gels. akt mRNA was assessed using cDNA probe HA. akt,
which recognises akt gene 1,2,3 (a gift from Julian Downward,
Cancer Research UK, London, UK). A glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) cDNA probe (Cancer
Research UK) was used as an RNA loading control.
Western blot analysis
Phosphorylated ERK1/2 were probed with 1:1,000 anti-phos-
pho-p44 ERK1 and p42 ERK2 monoclonal antibody (Cell Sig-
naling Technology). Non-phosphorylated ERK1/2 proteins
were probed with 1:1,000 anti-ERK2 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), which recognises both p44 ERK1
and p42 ERK2. Phosphorylated Akt was detected using
1:1,000 anti-phospho-Akt (Ser473) antibody (Cell Signaling
Technology) and total Akt1/2 protein was probed with 1:1000
anti-Akt1/2 (H136) (Santa Cruz). Secondary antibodies conju-
gated to HRP (GE Healthcare, Chalfont St Giles, UK) were
used at 1:1,000 dilution and visualised by enhanced chemilu-
minescence (GE Healthcare).
Recombinant GBP
Human recombinant GBP (Hu-r-GBP) was expressed in
Escherichia coli BL21(DE3) using hGal-1 cDNA in PET21a,
purified by lactose-agarose (Sigma) affinity chromatography
and purity assessed by matrix-assisted laser desorption/ioni-
zation-time of flight (MALDI-TOF) spectrometry.
Metabolic inhibitors
The mitogen-activated protein kinase kinase (MEK) inhibitor
UO126 (Calbiochem) was added to naïve MCF10A,
MCF10ACTx and MCF10AV12Ras cells 3 h after seeding at
concentrations of 10 M, 1 M, 100 nM and 10 nM (IC50 for
MEK1, 72 nM, MEK2, 58 nM) and cell viability, cell numbers
and inhibition of ERK1/2 were assessed in parallel.Breast Cancer Research    Vol 11 No 1    Wells and Mallucci 
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Figure 1
Events leading to apoptotic death in BT474 and SKBR3 breast cancer cells treated with human recombinant  galactoside binding protein (Hu-r- GBP) Events leading to apoptotic death in BT474 and SKBR3 breast cancer cells treated with human recombinant  galactoside binding protein 
(Hu-r-GBP). (a-b)Rate of cell proliferation and dose response to Hu-r-GBP. Dotted lines in growth curves define the time of occurrence of apop-
totic events. Values are means of triplicate cultures ± standard error of the mean (SEM). (c-d)Sequential expression of apoptotic events after treat-
ment with 30 nM Hu-r-GBP. Top to bottom: loss of mitochondrial membrane potential assessed by tetramethylrhodamine ester (TMRE); 
phosphatidylserine orientation at the plasma membrane assessed by annexin V staining; caspase 3 activity and DNA fragmentation (terminal deoxy-
nucleotidyl transferase (TdT)-mediated dUTP nick-end labelling (TUNEL)). Apoptotic cells are in circled areas. Values are percentages of cells in 
apoptosis. Left panels: controls, right panels: cells treated with 30 nM Hu-r-GBP. (e, h)Inhibition of class IA phosphoinositide 3-kinase (PI3K) activ-
ity by 30 nM Hu-r-GBP measured as phosphatidylinositol (3,4,5)-trisphosphate (PIP3) generated from immunoprecipitated PI3K in a kinase assay 
at 30°C, and assessed in a competitive ELISA. Values are means from triplicate readings ± SEM. (f, i) akt mRNA and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) mRNA levels. Left panels: controls, right panels: cells treated with 30 nM Hu-r-GBP. (g, j)Phosphorylated (Ser473) Akt 
and total Akt protein. Left panels: controls, right panels: cells treated with 30 nM Hu-r-GBP. (a-j) Hu-r-GBP added at 3 h after seeding. The data 
are representative of results obtained in three separate experiments.Available online http://breast-cancer-research.com/content/11/1/R2
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Results
Apoptosis: correlation between inhibition of PI3K 
activity and akt gene suppression
To determine whether GBP could overcome the strength of
endogenous mitogenic signalling in aggressive cancers we
examined BT474 and SKBR3 breast cancer cells that express
high levels of ErbB2 [33]. We found that GBP had virtually
no effect on cell replication (Figure 1a, b) until, after two to
three generation cycles, abrupt cell death was triggered by an
acute sequence of apoptotic events documented by changes
in mitochondrial membrane potential as assessed by TMRE
staining, by functional alteration of the plasma membrane as
assessed by annexin V staining, by caspase 3 activation and
by DNA fragmentation as assessed by TUNEL analysis (Figure
1c, d). We found, predictably, no changes in ERK phosphor-
ylation while cell replication continued unaffected but found,
as already observed in the normal cell context [32], that GBP
had affected PI3K function.
As cell phosphoinositide levels do not directly represent the
functional state of the PI3K enzyme, but are the result of PI3K
and PTEN activity, to estimate PI3K enzymatic activity we iso-
lated class IA PI3K by immunoprecipitation using an antibody
to the p85 adapter subunit and assessed the ability of the
coprecipitated p110 catalytic subunit to convert a standard
PIP2 to PIP3 in a kinase reaction by measuring the generated
PIP3 in a competitive ELISA. Figure 1e, h demonstrates that
downregulation of PI3K activity was an early event already
present at 6 h after the addition of GBP. Following inhibition
of PI3K activity, we detected loss of phosphorylated Akt and
loss of Akt protein preceding the apoptotic process (Figure
1g, j; right panels), though less promptly in the SKBR3 cells
where cell proliferation in the presence of GBP extended for
1 day longer (Figure 1b).
To investigate the cause for the loss of the Akt protein we
assessed akt mRNA levels. Figure 1f, i shows that akt mRNA,
clearly expressed in the unchallenged controls (left panels),
within 1 day from the addition of GBP, had become either
undetectable (Figure 1i, right panel) or very faintly expressed
(Figure 1f, right panel), a likely last effort to survive before
undergoing apoptotic death. Framed within a time sequence,
the above observations show that treatment with GBP
resulted in downregulation of PI3K activity, loss of akt mRNA,
loss of Akt and apoptosis.
Mitogenic input, akt mRNA levels and apoptosis
Based on the evidence shown in Figure 1, we hypothesised
that to elevate mitogenic input, corresponding elevated sur-
vival signalling may create conditions that foster mitogenic
expansion and cell survival, and also that akt gene expression
requires PI3K activity, and that by downregulation of PI3K
activity and consequent suppression of akt gene function,
GBP triggers apoptosis. To test the validity of this assump-
tion we experimentally enforced mitogenic pressure in non-
cancerous cells. We used spontaneously immortalised
MCF10A mammary ductal cells which have recognisable nor-
mal appearance and behaviour [34], MCF10A cells where
mitogenic input was enhanced by the addition of cholera toxin
[MCF10ACTx] which increases ERK activity via adenyl cyclase
upregulation [35], and MCFI0A cells stably transfected with
constitutively active p21 Ras mutated at valine 12
(MCF10AV12Ras), which strongly activates Raf-ERK signalling
[36].
We found that in the naïve MCF10A ductal cells where no
extra mitogenic pressure was enforced, treatment with GBP
did not lead to apoptosis (Figure 2a, d). By contrast, when cell
proliferation was boosted by cholera toxin or by V12Ras the
response to GBP was characterised by abrupt apoptotic
death after 2–3 replication cycles (Figure 2b, c and 2e, f),
mimicking the response of the BT474 and SKBR3 cells. Exam-
ination of the effect of GBP on PI3K showed that, as in Figure
1,  GBP had brought down and maintained PI3K activity
below basal levels in all cells (Figure 2g–i), but with a delay
from 6 to 24 h where the cells were driven by the strong
mitogenic signalling imposed by V12 Ras where the apoptotic
process was more gradual.
Figure 2 also shows that there was correlation between
mitogenic pressure and akt gene expression. Endogenous akt
mRNA levels which were barely detectable in the naïve
MCF10A cells not subjected to extra mitogenic pressure (Fig-
ure 2j, left panel), became clearly expressed where the
mitogenic input had been raised, whether by cholera toxin or
by V12 Ras (Figure 2k, i, left panels). Significantly, as in Figure
1, inhibition of PI3K activity was followed by loss of akt mRNA
(Figure 2j–l) and loss of phosphorylated Akt and Akt protein
(Figure 2m–o), but only followed by apoptosis where the akt
mRNA levels had been enhanced, a state which, conceivably,
conditions cells to vulnerability when exposed to the GBP
cytokine.
The indication from the above data and that shown in Figure 1
that strong mitogenic input, whether constitutive or induced, is
coupled to elevated survival signalling is underscored by the
evidence shown in Figure 3, where levels of phosphorylated
ERK and levels of akt mRNA (assessed in parallel) correlate. It
is of interest within the ERK/akt gene context that our obser-
vations bring to attention a putative new aspect in transcrip-
tional control, which extends the role of ERK from the
activation of cell cycle promoting genes [37] to the activation
of the akt gene, which promotes survival. Attempts to mecha-
nistically validate an ERK/akt mRNA link using MEK-ERK1/2
inhibitors were hampered by poor inhibition or by toxicity not
compatible with cell survival.
Notably, we found no evidence that raising active ERK levels,
whether by V12Ras or by cholera toxin, had any effect on PI3K
activity.Breast Cancer Research    Vol 11 No 1    Wells and Mallucci 
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Figure 2
Effects of cholera toxin (100 ng/ml) and RasV12 on MCF10A breast ductal cells and response to treatment with human recombinant  galactoside  binding protein (Hu-r-GBP) Effects of cholera toxin (100 ng/ml) and RasV12 on MCF10A breast ductal cells and response to treatment with human recombinant  
galactoside binding protein (Hu-r-GBP). (a-c) Cell proliferation and dose response to Hu-r-GBP. Values in growth curves are means from tripli-
cate cultures ± standard error of the mean (SEM). (d-f) Apoptotic response to treatment with 30 nM Hu-r-GBP. Apoptosis assessed by annexin V 
staining at day 3 after seeding. Apoptotic cells are in circled areas. Values are percentages of cells in apoptosis. Left panels: controls, right panels: 
cells treated with Hu-r-GBP. (g-i) Inhibition of Class IA phosphoinositide 3-kinase (PI3K) by 30 nM Hu-r-GBP assessed as described in Figure 1. 
Values are means from triplicate readings ± SEM. (j-l) akt mRNA and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA levels. Left pan-
els: controls, right panels: cells treated with 30 nM Hu-r-GBP. (m-o) Phosphorylated (Ser473) Akt and total Akt protein. Left panels: controls, right 
panels: cells treated with 30 nM Hu-r-GBP. (a-o) Hu-r-GBP added at 3 h after seeding. The data are representative of three separate experi-
ments. Cholera toxin was used to enhance mitogenic signalling via extracellular signal-regulated kinase (ERK) upregulation [35]. Constitutively 
expressed RasV12 was an endogenous source of enhanced mitogenic signalling [36].Available online http://breast-cancer-research.com/content/11/1/R2
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Cancer phenotype and cell vulnerability
The evidence that in the MCF10A ductal cells a shift in pheno-
typic behaviour as a consequence of enforced mitogenic pres-
sure changed the cellular response to GBP to mimic that of
the SKBR3 and BT474 cancer cells, raises the question of
whether a shift from a non-aggressive to an aggressive cancer
phenotype, as indicated by their in vitro behaviour, would
increase vulnerability to GBP. To relate mitogenic input to
response to GBP we examined non-invasive MCF-7 breast
cancer cells, which have low levels of ErbB2 [38], in their naïve
state and when treated with cholera toxin (MCF-7CTx). We
found that cholera toxin raised active ERK levels, accelerated
cell proliferation and accentuated akt gene expression (Figure
4a–c), thus changing the phenotypic aspect of the cells.
Examination of cell response to GBP showed that while, as
reported previously (38,39), in the naïve MCF-7 cells cell rep-
lication was inhibited by GBP (Figure 4d, open circles), the
MCF-7CTx cells resisted the growth inhibitory effect of GBP
to succumb, after 1–2 division cycles, to sudden death (Figure
4d, closed circles), again mimicking the response of the
BT474 and SKBR3 cancer cells.
Next, we investigated whether PI3K was again a primary
responder to the action of GBP and whether negation of akt
gene expression would be the consequence. To secure maxi-
mum expression of akt mRNA we used MCF-7CTx cells and
carried out time scale experiments using GBP in parallel with
wortmannin [39] and LY294002 [40], both pharmacological
inhibitors of the p110 catalytic subunit of PI3K, added at con-
centrations which would produce an effect similar to that of
GBP, and assessed PI3K activity and akt mRNA levels. Fig-
ure 4e–g shows that GBP lowered PI3K activity to a similar
extent as the two inhibitors, but with a more gradual kinetic, in
line with the action of a physiological effector molecule, and
that akt gene expression was negated when PI3K activity had
similarly descended by an approximately 35% quantum below
basal levels, in all three instances. This evidence indicates that
PI3K activity is a necessary requirement for akt gene expres-
sion, and that basal or close to basal endogenous levels are
sufficient.
The similarity of the effect exerted by GBP with that of wort-
mannin and LY294002 in regard of both inhibitory pattern and
the time required for the inhibitory action to come into effect
indicates that, as reported previously [32], treatment with
GBP may result in conformational changes which would
reduce the functional ability of the catalytic site of the p110
subunit of PI3K [12,13].
Discussion
The importance of PI3K in the fundamental processes that
lead to tumourigenesis has prompted the development of
small membrane permeable molecules aimed at targeting
components of the PI3K pathway for therapeutic intervention
against cancer. The present study suggests that this aim can
be achieved using the GBP cytokine, a natural inhibitor of
PI3K [32] whose physiological nature carries no chemothera-
peutic disadvantages.
Secreted by CD4+ and CD8+ -activated T cells [31] and by
somatic cells [30], endogenous GBP controls cell cycle
entry and S/G2 traverse [30]. In its recombinant form GBP
binds with high affinity (Kd 1.5 × 10-10 M) to approximately 5
× 104 receptors/cell, and at a concentration range of 1 to 20
nM GBP induces inhibition of cell proliferation via S/G2 cell
cycle arrest that, while reversible in normal cells, can lead can-
cer cells to death through routes that, via downregulation of
PI3K activity and suppression of Ras-ERK signalling [32],
result in cyclin kinase downregulation, deregulated E2F1
transactivation and apoptosis [41]. Cancer cells which
respond to GBP according to this pattern are non-invasive,
non-aggressive cells with low levels of ErbB2. They are typi-
fied by MCF-7 breast cancer cells and by p53 defective
Ramos lymphoma cells [41].
We now report that in breast cancer cells where ErbB2 is
overexpressed, GBP was unable to affect cell proliferation,
Figure 3
Extracellular signal-regulated kinase (ERK) levels and Akt mRNA levels  as expression of endogenous and enforced mitogenic input in BT474,  SKBR3, naïve MCF10A, MCF10ACTx and MCF10AV12Ras cells Extracellular signal-regulated kinase (ERK) levels and Akt mRNA 
levels as expression of endogenous and enforced mitogenic input 
in BT474, SKBR3, naïve MCF10A, MCF10ACTx and MCF10AV12Ras 
cells. Phosphorylated ERK, total ERK and Akt mRNA assessed in par-
allel at 48 h or 72 h (SKBR3) during mitogenic expansion. The data are 
from time scale assessments using equal amounts of protein and equal 
amounts of RNA and equal exposure times in separate gels due to 
space limitations when electrophoresing five different cell lines. Repeti-
tions of the experiments gave identical results.Breast Cancer Research    Vol 11 No 1    Wells and Mallucci 
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Figure 4
Response of MCF-7 breast cancer cells to cholera toxin and to cholera toxin and human recombinant  galactoside binding protein (Hu-r-GBP),  and effect of Hu-r-GBP and phosphoinositide 3-kinase (PI3K) inhibitors on akt gene expression Response of MCF-7 breast cancer cells to cholera toxin and to cholera toxin and human recombinant  galactoside binding protein (Hu-r-
GBP), and effect of Hu-r-GBP and phosphoinositide 3-kinase (PI3K) inhibitors on akt gene expression. (a-c) Extracellular signal-regulated 
kinase (ERK) levels, growth curves and Akt mRNA levels in naïve cells and in cells treated with 100 ng/ml cholera toxin added at the time of seeding. 
(a) Phosphorylated ERK and total ERK assessed at 48 h during mitogenic expansion. (b) Naïve cells (open circles); cells treated with 100 ng/ml 
cholera toxin added at the time of seeding (closed circles). Values are means of triplicate cultures ± standard error of the mean (SEM). (c) akt mRNA 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA levels. (d) Growth curves in response to treatment with Hu-r-GBP in naïve cells 
(open circles) and in cells treated with 100 ng/ml cholera toxin (closed circles) added at time of seeding. Hu-r-GBP (20 nM) was added 3 h after 
seeding. Values are means from triplicate cultures ± SEM. (e-g) Effect on downregulation of PI3K activity and akt mRNA in MCF-7CTx cells treated 
with 20 nM Hu-r-GBP, 10 nM wortmannin or 20 nM LY294002 added at 3 h after seeding. Phosphatidylinositol (3,4,5)-trisphosphate (PIP3) val-
ues are means of triplicate readings ± SEM. The data are representative of three separate experiments.Available online http://breast-cancer-research.com/content/11/1/R2
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but, while unable to quench redundant mitogenic signalling
and inhibit cell proliferation, by downregulating PI3K activity
and suppressing akt gene expression, GBP had strong ther-
apeutic efficacy that resulted in massive apoptotic death.
The relationship between mitogenic input and akt gene
expression and between akt mRNA levels and induction of
apoptosis by GBP as a consequence of downregulation of
PI3K activity was validated both in ductal cells and in non-inva-
sive MCF-7 cells where mitogenic signalling was experimen-
tally raised. In the MCF10A ductal cells, once phosphorylated
ERK and akt mRNA were boosted by upregulated mitogenic
input, and their normal-like behaviour changed to mimic that of
the BT474 and SKBR3 cancer cells, loss of akt mRNA
resulted in an intensity of apoptotic death similar to that of the
BT474 and SKBR3 cells where ErbB2 is overexpressed. In a
similar fashion, the MCF-7CTx cells where ERK and akt mRNA
had been experimentally upregulated, after overriding the
growth inhibitory effect of GBP, succumbed to total death.
This result poses the question of whether, where a shift into
malignancy enhances aggressiveness, the use of GBP might
conceivably be a potentially successful alternative to the use
of means directed at quenching constitutively active sources
of mitogenic signalling.
We have previously reported that luminal breast cells from
cosmetic reduction mammoplasties in short-term culture
arrested by GBP suffer no harm and resume growth. Addi-
tionally, we have reported that GBP has no harmful effect on
expanding T cells from healthy subjects nor, importantly, on
progenitor cells from bone marrow donors [41-43]. In this
study, we find that the naïve MCF10A mammary ductal cells
suffered little damage when exposed to GBP indicating that
loss of survival signalling is not harmful in the absence of
abnormal mitogenic pressure, thus offering one conceivable
explanation for the absence of harmful effect by GBP in the
ex vivo normal cells previously studied [41-43]. It is also of
interest that when mitogenic input was raised in the ductal
cells, the cells underwent apoptotic death when challenged by
GBP. This allows us to speculate that where an increase of
mitogenic signalling is a prime occurrence amongst events
that lead to oncogenesis, probably nascent cancer cells could
be eliminated in the healthy organism by the T cell-produced
endogenous GBP in a surveillance role [31]. A surveillance
role for GBP cytokine may be regarded as a conceivable
means by which the immune system may contribute to control-
ling malignancy.
Taken together, our results suggest a model where high
mitogenic input and enhanced ERK activity fosters cell survival
by upregulating akt gene expression, for which PI3K activity is
a requirement, and where, by downregulating PI3K activity and
negating akt gene function, GBP interrupts cancer cell reli-
ance on survival signalling.
To our knowledge, we have provided the first evidence indicat-
ing that PI3K activity is a requirement for akt gene expression
and that by targeting PI3K, GBP can therapeutically sup-
press akt gene expression and lead to death in tumour cells
where the ErbB2 oncoprotein is overexpressed while causing
no significant damage to mammary ductal cells.
Conclusion
PI3K is a central hub of signalling required for cell proliferation
and survival, critical in the evolution of aggressive tumourigen-
esis. The targeting of PI3K by the GBP cytokine provides a
novel mechanistic insight by which the GBP molecule can
overcome ErbB2 aggressiveness, a cause of poor prognosis.
The physiological nature of GBP and its selective efficacy
against cells that overexpress ErbB2 indicates that this mole-
cule has the potential to be successfully tested in clinical trials.
The study also offers a mechanistic rationale for the use of
GBP against other aggressive conditions, including xeno and
self immune responses.
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